INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Comprehensive Overview Of Alzheimer's Disease: Pathogenesis, Epidemiology, Experimental Models, And Therapeutic Approaches

Mohammed Sahad P., Mridhul Mohan P.*, E. Tamil Jothi

Department of Pharmacology, Devaki Amma Memorial College of Pharmacy, Chelembra, Malappuram Dt. Kerala. 673634.

ARTICLE INFO

Received: 30 April 2024
Accepted: 01 May 2024
Published: 03 May 2024

Keywords:
alzheimer's disease (ad), behavioral changes, ex vivo studies, non-pharmacological interventions, advance care planning.

DOI:
10.5281/zenodo.11108645

ABSTRACT

Alzheimer's disease (AD) is a prevalent neurodegenerative disorder characterized by progressive cognitive decline, memory loss, and behavioral changes. Dr. Alois Alzheimer's pioneering work in the early 20th century identified the hallmark pathological features of the disease. Despite advancements in understanding AD's molecular mechanisms, effective disease-modifying treatments remain elusive. The prevalence of AD is rising globally, particularly in aging populations, with projections indicating a significant increase by 2050. Various factors, including age, gender, ethnicity, and socioeconomic status, influence AD's epidemiology. Animal models and ex vivo studies play crucial roles in understanding AD pathophysiology and testing potential interventions. Behavioral assessments, such as the Mini-Mental State Examination (MMSE) and Neuropsychiatric Inventory (NPI), aid in diagnosing and monitoring AD progression. Current management strategies include pharmacological treatments, non-pharmacological interventions, caregiver support, and advance care planning. A holistic approach integrating research, clinical care, and public health efforts is essential to address the multifaceted challenges posed by AD and improve outcomes for affected individuals and their families.

INTRODUCTION

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and other cognitive impairments. It is the most common cause of dementia, a syndrome characterized by a decline in cognitive function severe enough to interfere with daily life and activities. AD typically develops slowly and worsens over time, ultimately leading to significant impairment in memory, thinking, and behavior.[1]

The history of Alzheimer's disease begins with its identification by Dr. Alois Alzheimer, a German psychiatrist and neuropathologist, in the early 20th

***Corresponding Author:** Mridhul Mohan P
Address: *Department of Pharmacology, Devaki Amma Memorial College of Pharmacy, Chelembra, Malappuram Dt. Kerala. 673634*
Email ✉: mridhulmohan236@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

century. In 1906, Dr. Alzheimer presented a case study of a 51-year-old woman named Auguste Deter, who exhibited profound memory loss, language difficulties, and behavioral changes. Upon her death, Dr. Alzheimer conducted a postmortem examination of her brain and observed abnormal protein deposits and nerve cell changes, which would later become known as the pathological hallmarks of AD.[1,2]

Dr. Alzheimer's seminal case study laid the foundation for our understanding of the disease and sparked further research into its etiology and pathology. Throughout the 20th century, advancements in neuroscience and medical imaging techniques allowed researchers to elucidate the molecular mechanisms underlying AD and develop diagnostic criteria for its identification. The identification of beta-amyloid plaques and neurofibrillary tangles as key pathological features of AD provided insight into the cellular processes driving neuronal degeneration in the brain. Subsequent research revealed the complex interplay between genetic predisposition, environmental factors, and age-related changes in the development and progression of AD. In the latter half of the 20th century, the development of cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, represented a significant milestone in the treatment of AD. These medications aimed to alleviate cognitive symptoms by increasing the availability of acetylcholine, a neurotransmitter essential for memory and learning processes.[3]

The 21st century witnessed a surge in research focused on identifying disease-modifying therapies capable of targeting the underlying pathology of AD, including beta-amyloid and tau protein aggregation. Despite significant progress in understanding the molecular mechanisms of AD, effective disease-modifying treatments remain elusive, highlighting the complexity and heterogeneity of the disease. Today, Alzheimer's disease represents a pressing public health challenge, with an aging population contributing to its increasing prevalence and societal impact. Efforts to advance early detection, improve care standards, and develop novel therapeutics continue to be paramount in addressing the growing burden of AD on individuals, families, and healthcare systems worldwide. The prevalence of Alzheimer's disease varies across regions and populations but is consistently higher among older adults. According to the World Health Organization (WHO), approximately 50 million people worldwide were living with dementia in 2020, with Alzheimer's disease accounting for the majority of cases. With population aging being a significant driver, projections suggest that the number of people living with dementia could nearly triple by 2050, reaching over 150 million globally.

Regional variations in AD prevalence reflect differences in demographic trends, genetic predisposition, socioeconomic factors, and healthcare infrastructure. Developed countries with aging populations tend to have higher prevalence rates of AD compared to low- and middle-income countries, where access to healthcare and diagnostic resources may be limited.[4,5]

EPIDEMIOLOGY OF ALZHEIMER'S DISEASE.

The epidemiology of Alzheimer's disease (AD) encompasses various factors, including age-related incidence and prevalence rates, gender and ethnic disparities, and socioeconomic influences. Understanding these epidemiological patterns is crucial for informing public health strategies and resource allocation for the prevention, diagnosis, and management of AD.

Age-related Incidence and Prevalence Rates:

Alzheimer's disease is primarily a disease of aging, with the risk increasing exponentially with advancing age. The prevalence of AD rises steeply

after the age of 65, doubling approximately every five years thereafter. While AD can occur in younger individuals (early-onset AD), the vast majority of cases occur in older adults (late-onset AD). Age-related changes in the brain, including the accumulation of beta-amyloid plaques and neurofibrillary tangles, contribute to the increased risk of AD with age.

Gender and Ethnic Disparities:

Studies have consistently shown that women are disproportionately affected by Alzheimer's disease compared to men. This gender disparity is partly attributable to differences in life expectancy, as women tend to live longer than men. However, emerging evidence suggests that biological, hormonal, and genetic factors may also contribute to the higher prevalence of AD in women. Ethnic and racial disparities in AD prevalence and risk have also been documented, with higher rates observed among certain population groups, including African Americans, Hispanics, and Indigenous populations. Socioeconomic factors, healthcare access, and environmental influences may contribute to these disparities, highlighting the importance of addressing health equity in AD research and interventions.

Socioeconomic Factors Influencing AD Prevalence:

Socioeconomic status (SES) plays a significant role in shaping the prevalence and burden of Alzheimer's disease. Studies have consistently shown an inverse relationship between SES indicators (e.g., education, income, occupation) and the risk of developing AD. Higher levels of education and socioeconomic attainment are associated with a reduced risk of AD and milder cognitive decline in later life. Access to healthcare, preventive services, and lifestyle factors (e.g., diet, physical activity, social engagement) may mediate the relationship between SES and AD risk. Disparities in healthcare access and quality of care may exacerbate socioeconomic inequalities in AD prevalence and outcomes, highlighting the need for targeted interventions and public health initiatives aimed at addressing social determinants of health.[6,7,8]

BEHAVIORAL ANIMAL MODEL STUDIES OF ALZHEIMER'S DISEASE

Behavioral studies using experimental animals in Alzheimer's disease research provide valuable insights into the cognitive, emotional, and functional changes associated with the disease, as well as potential interventions. These studies often utilize transgenic mouse models engineered to express human genes associated with Alzheimer's disease pathology, such as amyloid precursor protein (APP) and presenilin (PSEN) mutations. Here are several examples of behavioral studies conducted using experimental animals in Alzheimer's disease research:

1. Morris Water Maze:

The Morris water maze is a widely used behavioral test to assess spatial learning and memory in rodents, including transgenic mouse models of Alzheimer's disease. Mice are placed in a circular pool filled with opaque water and trained to locate a hidden platform using spatial cues in the environment. Spatial learning is measured by the time taken to find the platform (latency) and the efficiency of navigation strategies. Memory retention is assessed in probe trials where the platform is removed, and mice are allowed to search for the platform location.[9]

2. Novel Object Recognition:

The novel object recognition test evaluates recognition memory and exploratory behavior in rodents. Mice are exposed to two identical objects during a training session and then tested with one familiar object and one novel object. Recognition memory is inferred from the preference for exploring the novel object over the familiar object. Deficits in novel object recognition may indicate impairments in hippocampal-dependent memory processes associated with Alzheimer's disease.[10]

3. Fear Conditioning:

Fear conditioning paradigms assess associative learning and memory in rodents by pairing a neutral stimulus (e.g., tone) with an aversive stimulus (e.g., foot shock). Contextual fear conditioning involves exposing mice to a specific environment paired with the aversive stimulus, leading to conditioned fear responses in the same context. Cued fear conditioning pairs the neutral stimulus with the aversive stimulus, leading to fear responses in response to the conditioned cue. Fear conditioning tests can evaluate hippocampal- and amygdala-dependent memory processes implicated in Alzheimer's disease pathology.[11]

4. Y-Maze:

The Y-maze test assesses spatial working memory and spontaneous alternation behavior in rodents. Mice are allowed to explore a Y-shaped maze with three arms, and spontaneous alternation is measured as consecutive entries into different arms. Impaired spontaneous alternation behavior may indicate deficits in hippocampal-dependent working memory, a characteristic feature of Alzheimer's disease.[12]

5. Elevated Plus Maze:

The elevated plus maze test is used to assess anxiety-like behavior and exploration in rodents. Mice are placed on a plus-shaped maze with two open arms and two enclosed arms, and the time spent in each arm is recorded. Increased time spent in the enclosed arms and reduced exploration of the open arms may indicate heightened anxiety-like behavior associated with Alzheimer's disease pathology.[13]

6. Radial Arm Maze:

The radial arm maze is a classic behavioral test used to assess spatial learning and memory in rodents. Mice or rats are placed in a maze with several arms radiating from a central point, some of which contain food rewards. The animals must learn to navigate the maze and remember which arms they have visited to maximize their food reward intake. Impaired performance in the radial arm maze can indicate deficits in spatial memory and learning associated with Alzheimer's disease.[14]

7. Social Interaction Tests:

Social interaction tests assess sociability and social recognition memory in rodents. Mice or rats are placed in an arena with a novel conspecific (stranger mouse) and allowed to interact freely. Social behaviors, such as sniffing, grooming, and following, are quantified to measure sociability. Social recognition memory is assessed by reintroducing the familiar and novel conspecifics, and the time spent investigating each is recorded. Deficits in social interaction and recognition memory may reflect impairments in social cognition associated with Alzheimer's disease.[15]

8. T-maze:

The T-maze test evaluates spatial working memory and spontaneous alternation behavior in rodents. Mice or rats are placed in a T-shaped maze with two arms (start arm and choice arm), and the sequence of arm entries is recorded. Spontaneous alternation behavior is measured as the tendency to alternate between the start and choice arms across trials. Impaired spontaneous alternation behavior may indicate deficits in prefrontal cortex-mediated working memory associated with Alzheimer's disease.[16]

9. Object Location Memory:

Object location memory tests assess spatial memory and hippocampal-dependent memory processes in rodents. Mice or rats are exposed to two identical objects in an arena during a training session. In the test phase, one object is moved to a novel location, and the animal's ability to recognize the change in object location is assessed. Performance in object location memory tasks can reveal deficits in spatial memory consolidation and

retrieval associated with Alzheimer's disease pathology.[17]

10. Nesting Behavior:

Nesting behavior tests evaluate complex activities of daily living and functional impairments in rodents. Mice or rats are provided with nesting material (e.g., shredded paper) and observed for their ability to construct a nest. The quality of the nest is assessed based on parameters such as compactness, shape, and completeness. Impaired nesting behavior may indicate deficits in executive function, motivation, and social behavior associated with Alzheimer's disease.[18]



Fig. 1 various mazes and object recognition

EX VIVO EXPERIMENTAL STUDIES

Ex vivo experiments in Alzheimer's disease research involve studying biological processes, molecular mechanisms, and therapeutic interventions using tissue samples or cell cultures derived from animal models or human subjects. These experiments offer controlled conditions to investigate specific aspects of Alzheimer's disease pathology and test potential treatments. Here are several examples of ex vivo experiments commonly conducted in Alzheimer's disease research:

1. Brain Slice Cultures:

Brain slice cultures are prepared from brain tissue obtained from animal models or postmortem human brains. Slices are cut to preserve the cellular architecture and functional connectivity of the brain region of interest, such as the hippocampus or cortex. Brain slice cultures allow for the study of synaptic function, neuronal excitability, and neurodegenerative processes ex vivo. Experimental manipulations, such as exposure to amyloid-beta peptides or tau protein aggregates, can be performed to investigate their effects on neuronal viability and synaptic integrity.

2. Primary Neuronal Cultures:

Primary neuronal cultures are derived from dissociated brain tissue, typically from embryonic or neonatal rodents. Neurons are isolated and cultured in vitro to study cellular and molecular processes relevant to Alzheimer's disease pathology. Primary neuronal cultures allow for the investigation of synaptic plasticity, neurotoxicity, and protein aggregation in a controlled environment. Experimental treatments, such as drug compounds or genetic manipulations, can be applied to assess their effects on neuronal survival and function.

3. Organotypic Brain Slice Cultures:

Organotypic brain slice cultures maintain the three-dimensional structure and cellular diversity of brain tissue while allowing for experimental manipulations ex vivo. Slices are cultured at the interface between culture medium and air, mimicking in vivo conditions. Organotypic cultures provide a model system to study regional-specific aspects of Alzheimer's disease pathology, such as neuroinflammation, synaptic dysfunction, and neuronal death. Pharmacological interventions or genetic modifications can be applied to investigate potential therapeutic targets and mechanisms of action.

4. Cell-Based Assays:

Cell-based assays utilize immortalized cell lines or induced pluripotent stem cells (iPSCs) derived from patient samples to study Alzheimer's disease-related processes in vitro. Cell lines expressing human AD-related genes, such as APP or PSEN1/2 mutations, can be used to investigate amyloid-beta production, tau phosphorylation, and cellular toxicity. iPSC-derived neurons and glial cells offer a platform to study disease mechanisms, screen drug compounds, and develop personalized medicine approaches for Alzheimer's disease. High-throughput screening assays, such as enzyme-linked immunosorbent assays (ELISAs) and fluorescence-based assays, enable quantitative analysis of protein levels, enzymatic activities, and cellular functions in vitro.

5. Molecular and Biochemical Analyses:

Ex vivo experiments often involve molecular and biochemical analyses to characterize protein expression, post-translational modifications, and signalling pathways associated with Alzheimer's disease pathology. Techniques such as immunohistochemistry, immunofluorescence, Western blotting, and quantitative polymerase chain reaction (qPCR) are commonly used to assess protein localization, abundance, and gene expression levels in tissue samples or cell cultures. Pharmacological interventions or genetic manipulations can modulate protein levels, enzyme activities, or gene expression profiles to investigate their effects on disease-related processes ex vivo.

COGNITIVE ASSESSMENTSIN ALZHEIMER'S DISEASE

1. Mini-Mental State Examination (MMSE):

The MMSE is a widely used screening tool for assessing global cognitive function in adults. It evaluates various cognitive domains, including orientation to time and place, immediate and delayed recall, attention and calculation, language (naming, repetition, comprehension), and visuospatial abilities (copying a complex figure). The MMSE is scored out of 30 points, with lower scores indicating greater cognitive impairment. It is commonly used in clinical settings to screen for cognitive impairment, track disease progression, and monitor response to treatment in conditions such as Alzheimer's disease and other forms of dementia.[19]

2. Montreal Cognitive Assessment (MoCA):

The MoCA is another widely used screening instrument designed to assess multiple cognitive domains in adults. It evaluates memory (immediate and delayed recall), attention and concentration, executive functions (e.g., abstraction, cognitive flexibility, working memory), language (naming, comprehension, repetition), visuospatial abilities (clock drawing, cube copy), and orientation. The MoCA is scored out of 30 points, with lower scores indicating greater cognitive impairment. It is particularly useful for detecting mild cognitive impairment (MCI) and early stages of Alzheimer's disease, as it is more sensitive to subtle cognitive deficits compared to the MMSE.[20]

3. Neuropsychological Tests:

Neuropsychological tests refer to batteries of standardized assessments designed to evaluate specific cognitive domains and functions in detail. These tests are administered by trained

professionals and often include tasks targeting memory, executive function, language, attention, processing speed, and visuospatial skills.[21]

Examples of neuropsychological tests include:

Rey Auditory Verbal Learning Test: Assessing verbal learning and memory by presenting a list of words for immediate and delayed recall.

Trail Making Test: Evaluating visual attention, processing speed, and cognitive flexibility by connecting numbered dots in sequence (Part A) or alternating between numbers and letters (Part B).

Boston Naming Test: Measuring language and naming abilities by asking the individual to name pictured objects of increasing difficulty.

Clock Drawing Test: Assessing visuospatial and executive functions by requesting the individual to draw a clock face showing a specific time.

4. Functional Assessment Staging Test (FAST):

The FAST is a tool used to assess functional impairment and disease progression in activities of daily living (ADLs) among individuals with dementia. It consists of a series of seven stages representing progressively severe levels of functional decline, from normal independence (Stage 1) to severe dependence and loss of basic self-care abilities (Stage 7). The FAST assesses various domains of functional impairment, including self-care (e.g., dressing, feeding), mobility (e.g., walking, transferring), and social interaction (e.g., communication, recreational activities).It is often used in clinical research and practice to track the course of dementia, evaluate the effectiveness of interventions, and provide caregivers with information about anticipated changes in caregiving needs as the disease progresses.[22]

BEHAVIORAL AND PSYCHIATRIC ASSESSMENTS

1. Neuropsychiatric Inventory (NPI):

The Neuropsychiatric Inventory (NPI) is a comprehensive assessment tool used to evaluate behavioral and psychiatric symptoms in individuals with dementia. It was developed to assess a wide range of neuropsychiatric symptoms commonly observed in dementia, including agitation, aggression, depression, anxiety, hallucinations, delusions, irritability, disinhibition, euphoria, apathy, aberrant motor behavior, nighttime behavior disturbances, and appetite/eating abnormalities. The NPI is typically administered through structured interviews with caregivers or other knowledgeable informants who are familiar with the individual's behavior. For each symptom domain, caregivers rate the frequency and severity of symptoms, as well as the associated distress experienced by both the individual with dementia and the caregiver. The NPI yields scores for each symptom domain, facilitating quantitative assessment and tracking of changes over time. It is widely used in both clinical and research settings to characterize behavioral and psychiatric symptoms in dementia, monitor disease progression, guide treatment decisions, and evaluate the effectiveness of interventions.[23]

2. Cornell Scale for Depression in Dementia (CSDD):

The Cornell Scale for Depression in Dementia (CSDD) is a validated tool specifically designed to assess depressive symptoms in individuals with dementia. Depression is common in dementia but can be challenging to diagnose due to overlapping symptoms and communication difficulties. The CSDD consists of 19 items covering various domains of depressive symptoms, including mood, behavioral disturbances, physical signs, and cyclic functions. Caregivers or trained assessors rate the presence and severity of each symptom based on their observations and interactions with the individual with dementia. The CSDD provides a standardized and systematic approach to assessing depression in dementia, helping to differentiate depressive symptoms from other behavioral changes and informing treatment planning. It has

been widely used in both clinical practice and research studies to identify and monitor depressive symptoms, evaluate response to antidepressant therapy, and improve overall management of depression in individuals with dementia.[24]

3. Behavioral Rating Scale for Geriatric Patients (BGP):

The Behavioral Rating Scale for Geriatric Patients (BGP) is a caregiver-reported scale designed to assess various behavioral disturbances in dementia. It encompasses a range of behavioral symptoms commonly encountered in dementia, including apathy, irritability, agitation, wandering, disinhibition, verbal aggression, physical aggression, hallucinations, delusions, and sleep disturbances. Caregivers rate the frequency and severity of each behavioral symptom based on their observations and experiences over a defined period, typically the past week or month. The BGP provides a structured and standardized method for caregivers to report on the individual's behavior, facilitating communication with healthcare professionals and guiding treatment decisions. It can be used longitudinally to monitor changes in behavioral symptoms, assess treatment response, and optimize care plans for individuals with dementia and their caregivers.[25]

CURRENT TREATMENTS AND MANAGEMENT STRATEGIES FOR ALZHEIMER'S DISEASE (AD)

1. Pharmacological Treatments:

Cholinesterase Inhibitors: Medications such as donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne) are commonly prescribed to improve cognitive function and delay symptom progression in mild to moderate Alzheimer's disease. These drugs work by increasing levels of acetylcholine, a neurotransmitter involved in memory and learning, in the brain.

NMDA Receptor Antagonist: Memantine (Namenda) is another medication approved for the treatment of moderate to severe Alzheimer's disease. It works by regulating glutamate, a neurotransmitter involved in learning and memory, to help slow cognitive decline and improve symptoms.

Combination Therapy: In some cases, a combination of cholinesterase inhibitors and memantine may be prescribed to provide synergistic effects and better symptom management.[26,27]

2. Non-Pharmacological Interventions:

Cognitive Stimulation: Activities such as puzzles, memory games, and reminiscence therapy can help maintain cognitive function, stimulate neural pathways, and enhance overall well-being in individuals with Alzheimer's disease.

Physical Exercise: Regular physical activity, including aerobic exercise, strength training, and balance exercises, has been shown to improve mood, cognitive function, and physical health in individuals with Alzheimer's disease.

Social Engagement: Maintaining social connections, participating in social activities, and engaging in meaningful interactions with others can help reduce feelings of isolation, depression, and anxiety, while also promoting cognitive stimulation and emotional well-being.

Nutritional Support: A balanced diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats is important for overall health and may help support brain function and reduce the risk of cognitive decline in individuals with Alzheimer's disease.[28,29,30]

3. Caregiver Support and Education:

Caregiver Training: Education and training programs provide caregivers with information, resources, and strategies to better understand Alzheimer's disease, manage behavioral symptoms, provide personal care, and cope with the challenges of caregiving.

Support Groups: Support groups offer a platform for caregivers to connect with others facing similar challenges, share experiences, exchange advice,

and receive emotional support from peers and professionals.

Respite Care: Respite care services provide temporary relief for caregivers by offering short-term care for individuals with Alzheimer's disease, allowing caregivers to take breaks, attend to their own needs, and prevent burnout.[31,32]

4. Advance Care Planning:

Advance Directives: Advance directives, such as living wills and healthcare proxies, allow individuals to document their preferences for medical care and appoint a trusted individual to make healthcare decisions on their behalf if they become unable to do so in the future. Long-Term Care Planning: Long-term care planning involves discussions about housing options, financial planning, legal matters, and other considerations to ensure that individuals with Alzheimer's disease receive appropriate care and support as their needs change over time.[33,34]

CONCLUSION

Alzheimer's disease (AD) represents a significant global health challenge, characterized by progressive cognitive decline and profound impacts on individuals, families, and healthcare systems. The identification of key pathological hallmarks, such as beta-amyloid plaques and neurofibrillary tangles, has advanced our understanding of the disease, leading to the development of diagnostic criteria and pharmacological treatments aimed at alleviating cognitive symptoms. However, despite significant research efforts, effective disease-modifying therapies remain elusive, highlighting the complexity of AD and the need for continued exploration into its underlying mechanisms. Non-pharmacological interventions, including cognitive stimulation, physical exercise, social engagement, and caregiver support, play crucial roles in enhancing quality of life and managing the behavioral and psychological symptoms associated with AD.

Addressing the epidemiological patterns of AD, including age-related incidence, gender and ethnic disparities, and socioeconomic influences, is essential for informing public health strategies and resource allocation. Furthermore, behavioral animal model studies and ex vivo experimental approaches provide valuable insights into disease mechanisms and potential therapeutic targets. Moving forward, efforts to advance early detection, improve care standards, and develop novel therapeutics remain paramount in addressing the growing burden of AD worldwide. Collaborative research endeavors, interdisciplinary approaches, and advocacy for increased funding are essential to accelerate progress towards effective prevention, treatment, and ultimately, a cure for Alzheimer's disease.

REFERENCES

1. Alzheimer's Association. (2020). 2020 Alzheimer's Disease Facts and Figures. Alzheimer's & Dementia, 16(3), 391-460.
2. Hardy, J., &Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297(5580), 353-356.
3. Holtzman, D. M., and Morris, J. C. (2011). Goate, Alzheimer's disease: the challenge of the second century. Science Translational Medicine, 3(77), 77sr1.
4. Prince, M., Wimo, A., Guerchet, M., Ali, G. C., Wu, Y. T., &Prina, M. (2015). World Alzheimer Report 2015: The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. Alzheimer's Disease International (ADI).
5. Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., and Scheltens, P. (2014). Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. New England Journal of Medicine, 370(4), 322-333.

6. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nature Reviews Neurology. 2011 Mar;7(3):137-52.
7. Zhang XX, Tian Y, Wang ZT, Ma YH, Tan L, Yu JT. The epidemiology of Alzheimer's disease modifiable risk factors and prevention. The journal of prevention of Alzheimer's disease. 2021 Mar;8:313-21.
8. Qiu C, Kivipelto M, Von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues in clinical neuroscience. 2009 Jun 30;11(2):111-28.
9. Bromley-Brits K, Deng Y, Song W. Morris water maze test for learning and memory deficits in Alzheimer's disease model mice. JoVE (Journal of Visualized Experiments). 2011 Jul 20(53):e2920.
10. Grayson B, Leger M, Piercy C, Adamson L, Harte M, Neill JC. Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents. Behavioural brain research. 2015 May 15;285:176-93.
11. Hamann S, Monarch ES, Goldstein FC. Impaired fear conditioning in Alzheimer's disease. Neuropsychologia. 2002 Jan 1;40(8):1187-95.
12. Kraeuter AK, Guest PC, Sarnyai Z. The Y-maze for assessment of spatial working and reference memory in mice. Pre-clinical models: Techniques and protocols. 2019:105-11.
13. Pentkowski NS, Rogge-Obando KK, Donaldson TN, Bouquin SJ, Clark BJ. Anxiety and Alzheimer's disease: Behavioral analysis and neural basis in rodent models of Alzheimer's-related neuropathology. Neuroscience &Biobehavioral Reviews. 2021 Aug 1;127:647-58.
14. Lee JY, Kho S, Yoo HB, Park S, Choi JS, Kwon JS, Cha KR, Jung HY. Spatial memory impairments in amnestic mild cognitive impairment in a virtual radial arm maze. Neuropsychiatric disease and treatment. 2014 Apr 17:653-60.
15. Hsiao YH, Hung HC, Chen SH, Gean PW. Social interaction rescues memory deficit in an animal model of Alzheimer's disease by increasing BDNF-dependent hippocampal neurogenesis. Journal of Neuroscience. 2014 Dec 3;34(49):16207-19.
16. Davis KE, Burnett K, Gigg J. Water and T-maze protocols are equally efficient methods to assess spatial memory in 3xTg Alzheimer's disease mice. Behavioural brain research. 2017 Jul 28;331:54-66.
17. Kessels RP, Rijken S, Banningh LW, Van Schuylenborgh-Van Es N, Rikkert MG. Categorical spatial memory in patients with mild cognitive impairment and Alzheimer dementia: positional versus object-location recall. Journal of the International Neuropsychological Society. 2010 Jan;16(1):200-4.
18. Filali M, Lalonde R. Age-related cognitive decline and nesting behavior in an APPswe/PS1 bigenic model of Alzheimer's disease. Brain research. 2009 Sep 25;1292:93-9.
19. Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189-198.
20. Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, andChertkow, H. (2005). The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society, 53(4), 695-699.
21. Sunderland, T., Hill, J. L., Mellow, A. M., Lawlor, B. A., Gundersheimer, J., Newhouse,

P. A., &Grafman, J. H. (1989). Clock drawing in Alzheimer's disease. A novel measure of dementia severity. Journal of the American Geriatrics Society, 37(8), 725-729.

22. Reisberg, B., Ferris, S. H., De Leon, M. J., & Crook, T. (1982). The Global Deterioration Scale for assessment of primary degenerative dementia. American Journal of Psychiatry, 139(9), 1136-1139.
23. Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., &Gornbein, J. (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology, 44(12), 2308-2314.
24. Alexopoulos, G. S., Abrams, R. C., Young, R. C., &Shamoian, C. A. (1988). Cornell Scale for Depression in Dementia. Biological Psychiatry, 23(3), 271-284.
25. Cohen-Mansfield, J., &Billig, N. (1986). Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. Journal of the American Geriatrics Society, 34(10), 722-727.
26. Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., &Möbius, H. J. (2003). Memantine in moderate-to-severe Alzheimer's disease. New England Journal of Medicine, 348(14), 1333-1341.
27. Rogers, S. L., &Friedhoff, L. T. (1996). The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia, 7(6), 293-303.
28. Clare, L., & Woods, R. T. (2003). Cognitive training and cognitive rehabilitation for people with early-stage Alzheimer's disease: A review. Neuropsychological Rehabilitation, 13(3), 385-401.
29. Heyn, P., Abreu, B. C., &Ottenbacher, K. J. (2004). The effects of exercise training on elderly persons with cognitive impairment and dementia: A meta-analysis. Archives of Physical Medicine and Rehabilitation, 85(10), 1694-1704.
30. Fratiglioni, L., Paillard-Borg, S., &Winblad, B. (2004). An active and socially integrated lifestyle in late life might protect against dementia. The Lancet Neurology, 3(6), 343-353.
31. Tremont, G., Davis, J. D., Bishop, D. S., &Fortinsky, R. H. (2008). Telephone-delivered psychosocial intervention reduces burden in dementia caregivers. Dementia and Geriatric Cognitive Disorders, 25(2), 206-214.
32. Schulz, R., Belle, S. H., Czaja, S. J., McGinnis, K. A., Stevens, A., Zhang, S., ... & REACH Investigators. (2004). Long-term care placement of dementia patients and caregiver health and well-being. JAMA, 292(8), 961-967.
33. Brinkman-Stoppelenburg, A., Rietjens, J. A., & van der Heide, A. (2014). The effects of advance care planning on end-of-life care: a systematic review. Palliative Medicine, 28(8), 1000-1025.
34. Teno, J. M., Gruneir, A., Schwartz, Z., Nanda, A., Wetle, T., Bershadsky, B., ...&Mor, V. (2007). Association between advance directives and quality of end-of-life care: a national study. Journal of the American Geriatrics Society, 55(2), 189-194.

HOW TO CITE: Mohammed Sahad P, Mridhul Mohan P, E. Tamil Jothi Comprehensive Overview of Alzheimer's Disease: Pathogenesis, Epidemiology, Experimental Models, And Therapeutic Approaches, Int. J. of Pharm. Sci., 2024, Vol 2, Issue 5, 82-92. https://doi.org/ 10.5281/zenodo.11108645